EA201990289A1 - ANTIBODIES TO TGFβ, METHODS AND USES - Google Patents

ANTIBODIES TO TGFβ, METHODS AND USES

Info

Publication number
EA201990289A1
EA201990289A1 EA201990289A EA201990289A EA201990289A1 EA 201990289 A1 EA201990289 A1 EA 201990289A1 EA 201990289 A EA201990289 A EA 201990289A EA 201990289 A EA201990289 A EA 201990289A EA 201990289 A1 EA201990289 A1 EA 201990289A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protgfβ1
garp
complex
antibodies
antigen
Prior art date
Application number
EA201990289A
Other languages
Russian (ru)
Inventor
Грегори Дж. Карвен
Томас Шурпф
Кэтрин Тернер
Original Assignee
Сколар Рок, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сколар Рок, Инк. filed Critical Сколар Рок, Инк.
Priority claimed from PCT/US2017/042162 external-priority patent/WO2018013939A1/en
Publication of EA201990289A1 publication Critical patent/EA201990289A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Антитела, селективные к комплексу ProTGFβ1-GARP, полинуклеотиды, способные кодировать антитела, селективные к комплексу proTGFβ1-GARP, или антигенсвязывающие фрагменты, клетки, экспрессирующие антитела, селективные к комплексу proTGFβ1-GARP, или антигенсвязывающие фрагменты, а также ассоциированные векторы и меченные с возможностью обнаружения антитела, селективные к комплексу proTGFβ1-GARP, или антигенсвязывающие фрагменты могут быть использованы для усиления иммунного ответа у субъекта, например, против рака.Antibodies selective for ProTGFβ1-GARP complex, polynucleotides capable of encoding an antibody selective for the complex proTGFβ1-GARP, or antigen-binding fragments, cells expressing antibodies selective to the complex proTGFβ1-GARP, or antigen-binding fragments, as well as associated vectors and labeled with the possibility of Detection of antibodies selective for the proTGFβ1-GARP complex or antigen-binding fragments can be used to enhance the immune response in a subject, for example, against cancer.

EA201990289A 2016-08-05 2017-07-14 ANTIBODIES TO TGFβ, METHODS AND USES EA201990289A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662371355P 2016-08-05 2016-08-05
PCT/US2017/042162 WO2018013939A1 (en) 2016-07-14 2017-07-14 Tgfb antibodies, methods, and uses

Publications (1)

Publication Number Publication Date
EA201990289A1 true EA201990289A1 (en) 2019-06-28

Family

ID=66998669

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990289A EA201990289A1 (en) 2016-08-05 2017-07-14 ANTIBODIES TO TGFβ, METHODS AND USES

Country Status (1)

Country Link
EA (1) EA201990289A1 (en)

Similar Documents

Publication Publication Date Title
MX2019000514A (en) Tgfb antibodies, methods, and uses.
EA201892193A1 (en) CHEMICAL RECEPTORS TO FLT3 AND METHODS OF THEIR APPLICATION
CY1126115T1 (en) COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TUMOR TREATMENT
MY200602A (en) Antibodies against tim3 and uses thereof
PH12018501902A1 (en) Gitr antibodies, methods, and uses
EA201891709A1 (en) ANTIGENSBINKING PROTEINS, BINDING PD-L1
BR112016014022A2 (en) anti-cd3 antibodies, isolated nucleic acid, vector, host cell, anti-cd3 antibody production method, immunoconjugate, composition, use of anti-cd3 antibody, treatment methods, methods of enhancing immune function and kit
NZ739750A (en) Anti-tigit antibodies and methods of use
MX2017008978A (en) Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof.
CR20170079A (en) UNION AGENTS TO CD123 AND USES OF THESE
EA201400875A1 (en) ANTIBODIES TO CD47 AND METHODS OF THEIR APPLICATION
AR106555A1 (en) ANTI-IL1RAP ANTIBODIES, BINDING SPECIFIC MOLECULES THAT JOIN IL1RAP AND CD3, AND USES OF THESE
EA201791139A1 (en) HETERODIMERNYE ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
EA201690443A1 (en) BISPECIFIC MONOVALENT DIATELS, WHICH ARE CAPABLE TO CONNECT CD123 AND CD3 AND THEIR APPLICATIONS
PE20170665A1 (en) HUMANIZED ANTI-TAU ANTIBODIES
TR201903074T4 (en) Vectors for the expression of prostate associated antigens.
EA201501063A1 (en) CONNECTING HUMAN FcRn MODIFIED ANTIBODIES AND METHODS OF THEIR APPLICATION
CR20150575A (en) PAC1 HUMAN ANTIBODIES
MX2015012540A (en) Common light chain mouse.
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
MX2016011809A (en) Luminescent oxygen channeling immunoassay utilizing three antibodies and methods of production and use thereof.
WO2016023898A3 (en) Intracellular antigen binding
DK3455261T3 (en) ANTI-ROR2 ANTIBODIES, ANTIBODY FRAGMENTS, IMMUNE CONJUGATS THEREOF AND USES THEREOF
EA201792058A1 (en) VIROTHERAPY BY ANTIBODY COMBINATION
EA201890739A1 (en) ANTI-S100A8 FOR THE TREATMENT OF LEUKEMIA